Cantourage

Overview

Cantourage Group SE is a Berlin-headquartered medical cannabis company that sources pharmaceutical-grade cannabis from international cultivators and distributes it to pharmacies across Germany and other European markets, positioning itself as a platform connecting growers with the regulated European medical-cannabis supply chain. The company is led by co-founder and CEO Philip Schetter and has been listed in the Scale segment of the Frankfurt Stock Exchange since 2023 under the ticker HIGH (ISIN DE000A3DSV01).

Why this entity matters

Cantourage is one of the more visible publicly listed companies in Europe's medical cannabis sector, a market that has grown as Germany and other European countries have expanded legal frameworks for medical (and, in Germany's case from 2024, limited recreational-adjacent) cannabis access. As a public company, Cantourage discloses financial results on a recurring basis, giving outside observers a rare level of visibility into a sector where most competitors remain privately held. The company's own preliminary figures reported via EQS News show 2025 revenue rising to approximately €92.8 million — a company-reported preliminary figure that Startuprad.io has not independently audited.

Company or institutional background

Cantourage Group SE is headquartered in Berlin and was co-founded by Philip Schetter, who serves as CEO. The company's business model, per its own public materials and Startuprad.io's interview coverage, centers on acting as an intermediary platform that gives international medical-cannabis cultivators a regulated route into the German and wider European pharmacy market, handling import, quality assurance and distribution logistics. Cantourage began trading in the Scale segment of the Frankfurt Stock Exchange in 2023 under the ticker symbol HIGH. Per an EQS News company disclosure, Cantourage published preliminary figures for 2025 showing revenue rising to approximately €92.8 million; as with any company-reported preliminary figure, this should be treated as provisional pending the company's audited annual results, and Startuprad.io has not independently verified it.

Role in the ecosystem

Cantourage sits in the regulated medical-cannabis supply chain, positioned between international cultivators and the German/European pharmacy network, and is one of a small number of medical-cannabis companies with a public listing in the DACH region. It operates in a policy-sensitive sector shaped directly by German and EU cannabis regulation, which this record treats factually and without partisan framing, consistent with Startuprad.io's editorial policy on government- and policy-adjacent entities.

Selected relationships and affiliations

Cantourage is listed on the Frankfurt Stock Exchange (Scale segment, ticker HIGH, ISIN DE000A3DSV01). Its business model depends on relationships with international medical-cannabis cultivators as supply partners and with pharmacies across Germany and other European markets as distribution partners; specific partner names beyond those disclosed in the company's own public materials are outside the scope of this record.

Startuprad.io relevance

Startuprad.io interviewed Cantourage co-founder and CEO Philip Schetter directly in Episode 415, covering the company's growth, manufacturing and quality-assurance processes, its digital platform for wholesale pharmacy customers, and its market reach across Europe. That interview was later featured again in Startuprad.io's Top 5 Episodes of 2024 retrospective, indicating it was among the most engaged-with interviews Startuprad.io published that year.

Public source context

This record draws on Cantourage's own website https://www.cantourage.com , its investor-relations materials at https://www.cantourage.com/en/investors , its EQS News preliminary-figures disclosure, and Startuprad.io's own direct interview with CEO Philip Schetter (Episode 415). Revenue figures are as company-reported and preliminary at the time of this record and have not been independently audited by Startuprad.io.

Startuprad.io coverage

Trailblazing Medical Cannabis with Cantourage's Philip Schetter | Startuprad.io E 415
Published: 22 February 2024
Last updated: 20 September 2026
Coverage type: Interview
https://www.startuprad.io/post/trailblazing-medical-cannabis-with-cantourage-s-philip-schetter-startuprad-io-e-415

Top 5 Episodes 2024 | Trailblazing the Medical Cannabis Market: Cantourage's Journey with Philip Schetter
Published: 09 January 2025
Last updated: 20 September 2026
Coverage type: Announcement
https://www.startuprad.io/post/top-5-episodes-2024-trailblazing-the-medical-cannabis-market-cantourage

Need deeper entity intelligence?
→ https://www.startuprad.io/become-a-partner

Following Europe's medical cannabis sector through public companies like Cantourage? Entrepreneurs Vault members get the deeper operator read on regulatory-driven markets — how policy shifts translate into revenue, and what public disclosures reveal that private competitors don't have to share.
▶ YouTube Membership: https://www.youtube.com/startupradio/join
✉️ Substack: https://startupradio.substack.com/subscribe

About Startuprad.io

Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.

Canonical record: https://www.startuprad.io/entities/cantourage .